This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Butowski, N. A. Articles by Chang, S. M. Search for Related Content PubMed PubMed Citation Articles by Butowski, N. A. Articles by Chang, S. M. Social Bookmarking                            What's this?

Diagnosis and Treatment of Recurrent High-Grade Astrocytoma

From the Departments of Neurological Surgery and Radiation Oncology, University of California, San Francisco, San Francisco, CA

Address reprint requests to S.M. Chang, MD, Department of Neurological Surgery, University of California, San Francisco, 400 Parnassus Ave, A-808, San Francisco, CA 94143-0350; e-mail: changs{at}neurosurg.ucsf.edu

High-grade gliomas represent a significant source of cancer-related death, and usually recur despite treatment. In this analysis of current brain tumor medicine, we review diagnosis, standard treatment, and emerging therapies for recurrent astrocytomas. Difficulties in interpreting radiographic evidence, especially with regard to differentiating between tumor and necrosis, present a formidable challenge. The most accurate diagnoses come from tissue confirmation of recurrent tumor, but a combination of imaging techniques, such as magnetic resonance spectroscopy imaging, may also be relevant for diagnosis. Repeat resection can prolong life, but repeat irradiation of the brain poses serious risks and results in necrosis of healthy brain tissue; therefore, reirradiation is usually not offered to patients with recurrent tumors. We describe the use of conventional radiotherapy, intensity-modulated radiotherapy, brachytherapy, radiosurgery, and photodynamic therapy for recurrent high-grade glioma. The use of chemotherapy is limited by drug distribution and toxicity, but the development of new drug-delivery techniques such as convection-enhanced delivery, which delivers therapeutic molecules at an effective concentration directly to the brain, may provide a way to reduce systemic exposure to cytotoxic agents. We also discuss targeted therapies designed to inhibit aberrant cell-signaling pathways, as well as new experimental therapies such as immunotherapy. The treatment of this devastating disease has so far been met with limited success, but emerging knowledge of neuroscience and the development of novel therapeutic agents will likely give patients new options and require the neuro-oncology community to redefine clinical trial design and strategy continually.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Li, H.-Y. Guan, L.-Y. Gong, L.-B. Song, N. Zhang, J. Wu, J. Yuan, Y.-J. Zheng, Z.-S. Huang, and M. Li Clinical Significance of Sphingosine Kinase-1 Expression in Human Astrocytomas Progression and Overall Patient Survival Clin. Cancer Res., November 1, 2008; 14(21): 6996 - 7003. [Abstract] [Full Text] [PDF]

				L. W Buie and J. Valgus Bevacizumab: A Treatment Option for Recurrent Glioblastoma Multiforme Ann. Pharmacother., October 1, 2008; 42(10): 1486 - 1490. [Abstract] [Full Text] [PDF]

				P. Y. Wen and S. Kesari Malignant Gliomas in Adults N. Engl. J. Med., July 31, 2008; 359(5): 492 - 507. [Full Text] [PDF]

				K. Pinker, I.M. Noebauer-Huhmann, I. Stavrou, R. Hoeftberger, P. Szomolanyi, G. Karanikas, M. Weber, A. Stadlbauer, E. Knosp, K. Friedrich, et al. High-Resolution Contrast-Enhanced, Susceptibility-Weighted MR Imaging at 3T in Patients with Brain Tumors: Correlation with Positron-Emission Tomography and Histopathologic Findings AJNR Am. J. Neuroradiol., August 1, 2007; 28(7): 1280 - 1286. [Abstract] [Full Text] [PDF]

				B. M. Costa, P. Ferreira, S. Costa, P. Canedo, P. Oliveira, A. Silva, F. Pardal, G. Suriano, J. C. Machado, J. M. Lopes, et al. Association between Functional EGF+61 Polymorphism and Glioma Risk Clin. Cancer Res., May 1, 2007; 13(9): 2621 - 2626. [Abstract] [Full Text] [PDF]

				T. S. Lawrence, J. C. Buckner, and F. F. Lang CNS Malignancies: At Last, Real Progress J. Clin. Oncol., March 10, 2006; 24(8): 1225 - 1227. [Full Text] [PDF]